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Background/Objective: Pancreatic Cancer Disease Impact (PACADI) score measures the impact of
pancreatic cancer (PC) on important health dimensions, selected by patients. The aim of this single center
study was to test the psychometric performance of the Pancreatic Cancer Disease Impact (PACADI) score.
Methods: Patients with suspected pancreatic cancer (PC) completed PACADI, the EuroQol-5D (EQ-5D
index) and Edmonton Symptom Assessment System (ESAS) in this longitudinal observational study.
Measures were compared across patients with PC (n¼ 210), other malignant lesions (OML) (n¼ 109) and
non-malignant lesions (NML) (n¼ 41). Associations, test-retest and internal consistency reliability, lon-
gitudinal changes, sensitivity to change and prediction of mortality during the first year were examined
in patients with PC.
Results: The three measures discriminated between PC and OML. The PACADI score correlated strongly at
baseline (n¼ 199)/after three months (n¼ 85) with the EQ-5D index and ESAS “sense of well-being”
(0.64 and 0.66/0.73 and 0.69, p < 0.001, respectively), showed high test-retest reliability (ICC 0.84) and
very good internal consistency reliability (Cronbach's alpha 0.81e0.85) across all visits. Scores improved
over time at 3, 6, 9 and 12 months for survivors, and standardized response mean (SRM) for improve-
ment between 2 and 3 months (n¼ 44) was 0.80 (PACADI), 0.59 (EQ-5D index) and 0.69 (ESAS “sense of
well-being”). The PACADI score significantly predicted mortality within the first year (p¼ 0.02) in
contrast to the EQ-5D index and ESAS “sense of well-being”.
Conclusion: This study showed satisfactory psychometric performance of the PACADI score. The results
support its use in clinical practice and intervention trials.
© 2019 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In spite of progress in the treatment of some cancer diagnoses in
terms of decreased mortality [1], pancreatic cancer (PC) remains a
major health problem, both regarding disease course and survival
[2]. Challenges, among others, are late diagnosis and relative
paucity of research funding for PC. These challenges are shared




B.V. This is an open access article uto hopefully double the 5-year survival by 2029 [3]. However, some
recent studies have indicated progress in the treatment and prog-
nosis of PC [4e6]. These progresses are dependent on valid mea-
sures to capture improvement.
Valid measures may also raise the awareness of symptoms and
increase the detection of diagnosis and treatment. The Food and
Drug Administration (FDA) and the European Medicines Agency
(EMA) recommend researchers to provide evidence of benefit in
Patient Reported OutcomeMeasures (PROM) to achieve approval of
new medications [7]. However, extensive questionnaires with
limited perceived relevance to the informants may negatively affect
completion and respondent rates [8]. Assessing PROM in PC has
unfortunately been rarely reported and appraised in trials,
compared to survival as an outcome measure [9].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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changes than generic PROM [10]. Furthermore, it is still an open
questionwhich dimensions to include in PROM questionnaires, and
there is a diversity of PROM dimensions in use for patients with PC
[11,12].
Lack of concordance in reporting symptoms between patients
and clinicians [13] indicates a need for questionnaires that ask
questions which primarily reflects relevance and importance to the
patients.
We have previously reported the development of a brief, fully
patient-derived, disease specific questionnaire that can be
expressed with a score, the PAncreatic CAncer Disease Impact
(PACADI) score [14].
A preliminary validation has been performed [14]. However, we
are now able to provide a more complete study on the full psy-
chometric performance of the PACADI score. Thus, the aim of this
study was to examine the psychometric performance of the PACADI
score, both in a cross-sectional and longitudinal perspective with
simultaneous examination of EuroQol-5D (EQ-5D) index [15] and
the global question “sense of well-being” in Edmonton Symptom
Assessment System (ESAS) [16].2. Patients and methods
A couple of purely patient derived PROM have been developed
for patients with rheumatic diseases [17e19] and the methodo-
logical approach was also a model for the development of the
PACADI score.
Adult (>18 years) patients with suspected PC (n¼ 360) who
were referred to a tertiary hepato-pancreato-biliary (HPB) center,
were included in this study from 2012 to 2016. The patients were
categorized into three diagnostic groups; PC (n¼ 210), other ma-
lignant lesions (OML) (n¼ 109), and non-malignant lesions (NML)Table 1
Baseline characteristics across three diagnostic groups (n¼ 360) (discriminatory validity
PC n¼ 210 (58.7%) OML n¼ 109
Age 67.5 (10.4) 65.8 (11.1)
Females (%) 49.3 38.9
Weight 71.7 (14.9) 76.0 (13.9)
Weight lossa 7.7 (8.7) 6.4 (6.5)
BMI 24.1 (4.3) 25.1 (4.0)
BMI changea 2.6 (3.0) 2.1 (2.1)
PACADI dimensions
Pain/discomfort 3.0 (2.9) 2.4 (2.7)
Anxiety 4.0 (3.1) 3.4 (2.7)
Loss of appetite 3.6 (3.4) 2.7 (2.9)
Itchiness 2.4 (3.6) 2.8 (3.6)
Fatigue 4.4 (2.9) 3.5 (2.9)
Nausea 2.1 (2.9) 1.7 (2.8)
Dry mouth 3.4 (3.1) 2.9 (2.9)
Bowel and/or digestive problems 3.6 (3.1) 2.7 (3.0)
PACADI score 3.4 (2.1) 2.8 (2.0)
EQ-5D index 0.60 (0.30) 0.70 (0.26)
ESAS dimensions
Pain at rest 2.0 (2.5) 1.4 (2.2)
Pain at movement 2.2 (2.6) 1.5 (2.5)
Fatigue 3.9 (3.00) 3.2 (2.9)
Nausea 1.6 (2.7) 1.5 (2.7)
Dyspnea 1.3 (2.3) 1.6 (2.4)
Dry mouth 3.0 (3.0) 2.6 (2.8)
Loss of appetite 3.3 (3.3) 2.1 (2.6)
Anxiety 3.3 (3.1) 2.9 (2.7)
Depression 2.6 (3.0) 2.0 (2.3)
Sense of well-being 3.7 (2.9) 3.1 (2.7)
PC¼Pancreatic cancer. OML¼ Other malignant lesions. NML¼ Non malignant lesions.
a From disease onset to baseline.
b ANOVA/chi-square, as appropriate.(n¼ 41) (Table 1). Our aim was to include 200 patients with
confirmed diagnoses of PC (i.e. ICD10 C25.0e3) [20].
Data on the confirmation of diagnoses by imaging modalities,
cytology, histology or histology in combinationwith surgery as well
as stage, were collected after enrollment (Table 2).2.1. Design and data collection
Two authors (TB, MD, surgeon/TH, RN, researcher) recruited
patients during their diagnostic appointments to take part in a
study to select dimensions for a PROM to assess PC. Data were
collected at inclusion (baseline) and after 1, 2, 3, 6, 9 and 12months
follow-up. Age, gender as well as body weight and height to
calculate body mass index (BMI) were recorded in the case report
form (CRF) at baseline. Since weight loss is a recognized symptom
in PC [21], regular body weight prior to disease onset was also
recorded.2.2. Instruments
The CRF included the PACADI questionnaire which consists of 8
dimensions prioritized by patients (Pain/discomfort, Anxiety, Loss
of appetite, Itchiness, Fatigue, Nausea, Dry mouth, Bowel/digestive
problems), without further subscales [14]. Responses were given
for each dimension on a numeric rating scale (NRS) 0e10 at every
visit. Past week was the time frame for the responses [14]. Anchors
were “not at all” (0) and “worst possible” [ 10]. According to pa-
tients’ rankings for priority, we calculated a relative weight for each
dimension [(14]. The PACADI score (range 0e10) was calculated by
multiplying NRS values (range 0e10) by the final weight of each
dimension and sum up the products [14]: NRS pain/discomfort
value x 0.16þNRS fatigue value x 0.16þNRS bowel/digestion value
x 0.15 þ NRS loss of appetite value x 0.14 þ NRS anxiety value x).
(30.0%) NML n¼ 41 (11.3%) p-valueb Total (n¼ 360)
65.8 (11.3) 0.35 66.8 (10.7)
39.0 0.15 45.0%
75.5 (15.0) 0.037 73.5 (14.7)
6.3 (8.2) 0.34 7.1 (8.0)
25.1 (4.0) 0.11 24.5 (4.2)
2.2 (2.8) 0.29 2.4 (2.7)
3.0 (3.0) 0.14 2.8 (2.8)
3.3 (2.5) 0.14 3.7 (2.9)
3.0 (3.3) 0.06 3.2 (3.3)
1.9 (2.7) 0.39 2.4 (3.59
3.6 (3.1) 0.039 4.0 (3.0)
2.0 (2.7) 0.64 2.0 (2.8)
3.5 (3.6) 0.35 3.3 (3.1)
3.1 (3.0) 0.05 3.3 (3.1)
3.0 (2.3) 0.045 3.2 (2.1)
0.66 (0.33) 0.045 0.64 (0.29
2.0 (2.5) 0.09 1.8 (2.5)
2.4 (2.7) 0.07 2.0 (2.6)
3.2 (3.1) 0.07 3.6 (3.0)
1.4 (2.4) 0.89 1.6 (2.7)
2.3 (3.2) 0.043 1.5 (2.5)
3.2 (3.6) 0.49 2.9 (3.0)
2.6 (3.1) 0.004 2.9 (3.1)
3.3 (3.0) 0.52 3.2 (3.0)
2.6 (3.0) 0.20 2.4 (2.8)
3.2 (2.8) 0.17 3.4 (2.8)
Table 2
Description of the stage, performed surgery and diagnostic methods in the three diagnostic groups.
PC n¼ 210 (58.7%) OML n¼ 109 (30.0%) NML n¼ 41 (11.3%) p-valuea
Stage
Localized 43.5 68.5 100.0 0.000
Locally advanced 35.4 20.4 0
Metastatic 21.1 11.1 0
Surgery 72.3 89.9 73.2 0.001
Main diagnostic tool for confirmation of diagnoses
Imaging modality 9.2 3.9 10.3 0.054
Cytology 9.7 1.0 7.7
Histology 62.8 72.8 66.7
Histology and surgery 18.4 22.3 15.4
PC¼Pancreatic cancer. OML¼ Other malignant lesions. NML¼ Non malignant lesions.
a Chi-square.
T. Heiberg et al. / Pancreatology 19 (2019) 971e978 9730.13 þ NRS dry mouth value x 0.11 þ NRS itchiness value x
0.08 þ NRS nausea value x 0.07. This algorithm emphasizes the
relative importance of each dimension to the patients [14].
We used a one-dimensional anchor for the patients’ subjective
perception of change in health condition, over the last month, i.e.
since last visit. Response options were improved, unchanged or
worse [22].
Other questionnaires in the CRF included EQ-5D index [15] with
five dimensions (three dimensions addressing physical function,
and the two last items addressing anxiety and pain), each with 3
levels of response options (none/minor, moderate or major prob-
lem). Calculation of the EQ-5D index utility score was based on the
original algorithm (better health with increasing values), ranging
from below zero to 1.0 (perfect health) [15]. Furthermore, the ESAS
[16] with 10 items was included also with responses on NRS 0e10
but with regard to the current day as the time frame [16]. ESAS
“sense of well-being” (question 10) was considered as a disease-
specific global PROM for PC to enable reasonable comparisons.
ESAS has been developed to assess PC with a special emphasize on
the palliative phase [16].3. Statistical analyses
Baseline characteristics and other descriptive data are presented
as mean (SD) for continuous variables and counts/percentages for
categorical variables. ANOVA was used to compare the three diag-
nostic groups (PC, OML and NML) and to examine the discriminant
validity of PACADI, EQ-5D index and ESAS “sense of well-being”.
We also compared PC versus OML, PC versus NML and OML
versus NML, using independent samples t-tests. The differences at
baseline and corresponding 95% CI are presented (Table 3).
We included gender and age as covariates in univariate analyses
of variance to check for bias of covariates in the examination of the
discriminatory strength of the PACADI score across diagnostic
groups. Body weight as a disease manifestation [23] was notTable 3
Within-group tests of the diagnostic groups.
PROM Comparisons Sig. (2-tailed)
PACADI score PC vs OML 0.012
PC vs NML 0.318
OML vs NML 0.414
EQ-5D index PC vs OML 0.013
PC vs NML 0.334
OML vs NML 0.466
ESAS “Sense of well-being” PC vs OML 0.054
PC vs NML 0.426
OML vs NML 0.542
Two samples t-tests (Equal variance assumed).included as a covariate.
We used independent samples t-test to examine differences in
variables at baseline between patients who completed and patients
who did not complete all follow-ups.
No imputation for missing data was used. All analyses were
conducted from baseline to each time point on the remaining
responding sample, using paired sample t-tests.
As the data according to histograms and comparingmean versus
median were not normally distributed, Spearman's correlation was
used in cross-sectional analyses to examine validity at baseline and
at the 3-month follow-up examination. The levels of correlation
based on Spearman's rho were defined as very weak (0.00e0.19),
weak (0.20e0.39), moderate (0.40e0.59, strong (0.60e0.79) or
very strong (0.80e1.00). Significant correlations were recorded as
either p< 0.05 or p< 0.001.
The Intraclass Correlation Coefficient (ICC) was calculated for
examination of test-retest reliability. The test-retest was performed
with an interval from baseline to 1 month in patients reporting to
be unchanged, i.e. with stable disease status on the global anchor
question for patients’ subjective perception of change in health
condition. Values less than 0.5, between 0.5 and 0.75, between 0.75
and 0.90, and greater than 0.90 were considered indicative of poor,
moderate, good, and excellent reliability, respectively [24].
To check for internal consistency, we also calculated Cronbach's
alpha across dimensions for the two composite measures PACADI
score and EQ-5D index at baseline and at 3-, 6-, 9- and 12-month
follow-up.
Paired samples T-tests were applied to examine longitudinal
changes in PROM (PACADI score, EQ-5D index and ESAS) for pa-
tients with PC over time at all visits.
These data were also used to examine standardized response
mean (SRM for the PACADI score, EQ-5D index and ESAS “sense of
well-being” in the subset of patients who reported disease
improvement during the last month at three months, since this is
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month 3 divided by the SD of the change. Cohen definitions for
effect size (ES) can also be used for SRM: ‘trivial’ ES< 0.20, ‘small’
ES 0.20< 0.50, ‘moderate’ ES 0.50< 0.80, or large ES 0.80
[25].
Finally, we used separate Cox Regression analyses to examine
prediction of early (before 12 months) mortality for the PACADI
score, EQ-5D index and ESAS “sense of well-being” with adjust-
ment for age and gender.
Datawere storedwith a numeric identifier in a separate, secured
central hospital research server. The code list was securely stored,
only accessible for the principal investigators. The regional ethical
committee approved the protocol and patient information/consent
form (REK no.265-08412c). The privacy protection supervisor
evaluated and accepted the data-handling procedures. All patients
signed a written informed consent before inclusion.4. Results
4.1. Patients
Patients with suspected PC (n¼ 360, mean (SD) age 66.8 (10.7),
45.0% females) were consecutively included between 2012 and
2016. Longitudinal follow-up was performed from May 2013. The
number of patients at baseline with PC was 210 (58.7%), OML 109
(30.0%) and NML 41 (11.3%). Three patients declined to be enrolled
in the study. Eleven patients did not complete PACADI at baseline,
but they completed PACADI at later time points.
The groups were comparable for clinical characteristics except
for body weight, stage and performance of surgery (Table 1). The
results of adjusted univariate analyses of variance were similar to
the ANOVA analyses. Gender was a significant covariate to the
PACADI score (p¼ 0.007), whereas age was not (p¼ 0.40).
Stage, performed surgery and diagnostic methods used in our
material showed that surgery was less frequent in patients with PC
than in the other two groups, with the highest percentage of locally
advanced and metastatic disease. Most patients were diagnosed
with histology or a combination of surgery and histology (Table 2).4.2. Discrimination
The PACADI score at baseline was significantly higher
(p¼ 0.045) in the patients with PC compared to the other two
groups. The EQ-5D index also discriminated significantly between
the diagnostic groups (Table 1). PACADI single dimensions showed
significant discrimination between the diagnostic groups for “fa-
tigue” and “bowel/digestive problems” (p¼ 0.039/0.005) and
borderline for “loss of appetite” (p¼ 0.06). ESAS “sense of well-
being” (global) did not significantly discriminate between the
diagnostic groups. However, ESAS single dimensions showed sig-
nificant discriminatory trait for “loss of appetite” (p¼ 0.004)
(Table 1).
Within-group comparisons across the three diagnostic groups,
using the three main measures (PACADI score, EQ-5D index and
ESAS “sense of well-being”) showed that PACADI and EQ-5D index
discriminated significantly between PC vs OML, whereas ESAS
“Sense of well-being” showed a borderline significance between PC
and OML. Differences between PC and NML were not statistically
significant (Table 3).
The two variables that were significantly different at baseline
between patients who completed the study to the 12-month
follow-up and those who did not, were “bowel and/or digestive
problems” (p¼ 0.02) and EQ-5D (p¼ 0.001).4.3. Correlations
Correlations between PACADI score, EQ-5D index and ESAS
“sense of well-being” as global measures at baseline/after three
months were significant (p< 0.001) and were strong to EQ-5D in-
dex (0.64/-0.73) and to ESAS “sense of well-being” (0.66/0.69)
(Table 4). Most of the six overlapping dimensions between PACADI
and ESAS correlated very strongly both at baseline and at the 3-
month visit. Correlations between other dimensions varied from
moderate to very weak (Table 4).
4.4. Reliability
Test-retest reliability testing in patients with stable condition
(n¼ 14), using an interval from baseline to one month, showed ICC
0.84 for PACADI score in patients with PC and 0.74 for all patients
with stable condition (n¼ 34) (Table 5). ICC for EQ-5D index were
in patients with PC/all patients 0.88/0.83 and for ESAS “sense of
well-being” 0.85/0.72 (Table 5). The ICC of the three global mea-
sures is regarded as good in patients with PC [24].
Internal consistency reliability assessed by Cronbach's alpha for
patients with PC was consistently very high across visits at base-
line/3/6/9/12 months for the PACADI score (0.83/0.85/0.81/0.84/
0.84, respectively). For the EQ-5D index, Cronbach's alpha showed
moderate to very high internal consistency reliability at the same
time points (0.58/0.82/0.66/0.70/0.72, respectively.
4.5. Longitudinal changes
Longitudinal examinations showed significant improvement
(p< 0.05 - p< 0.001) in PACADI score for patients with PC from
baseline (n¼ 199) to 3 (n¼ 85), 6 (n¼ 76), 9 (n¼ 61) and 12
(n¼ 51) months (Table 6). The EQ-5D index did not significantly
improve, and ESAS “sense of well-being” had improved signifi-
cantly after 9 and 12 months. For two single dimensions in PACADI,
“anxiety” and “itchiness”, the improvement was significant from
baseline to all other time points (p< 0.001). Also “loss of appetite”,
“fatigue” and “dry mouth” improved during the 12-month follow-
up. For the single dimensions in ESAS, “loss of appetite”, “fatigue”
and “anxiety” improved (Table 6).
Responsiveness of PACADI score was examined in patients who
reported improvement at three months since the previous visit at 2
months, because this is the time when patients usually return to
preoperative values after surgery [26]. SRM was large for PACADI
score (0.80, n¼ 44), moderate for EQ-5D index (0.59, n¼ 43) as
well as for ESAS “sense of well-being” (0.69, n¼ 42).
4.6. Prediction of mortality
Out of the three global measures, only PACADI score signifi-
cantly (p¼ 0.02) predictedmortality during the first year follow-up
of patients with PC, adjusted for age and gender in the analyses
(Table 7). The three dimensions of the PACADI score that contrib-
uted significantly to this psychometric property, were “pain/
discomfort” (p¼ 0.004), “fatigue” (p¼ 0.034) and “bowel and/or
digestive problems” (p¼ 0.02).
5. Discussion
The PACADI score is a disease-specific patient-reported outcome
measure for patients with PC. We have previously reported on the
development of the score and presented some preliminary data on
the psychometric performance [14]. PACADI is intended for use
both in clinical practice and in science. However, we expect that the
individual dimensions will be more important for clinical practice,
Table 4
Spearman's correlations between PACADI score, EQ-5D index and ESAS at baseline/3 months in patients (n¼ 199/85) with pancreatic cancer (concurrent validity).
Baseline EQ-5D index ESAS
Pain at rest Pain at
movement




































































































































































Intraclass correlation coefficient (ICC) at baseline and during follow-up after one month in patients with pancreatic cancer/all patients who reported stable disease (test-retest
reliability).
Pancreatic cancer n¼ 14 All patients n¼ 34
Mean baseline Mean after one month ICC Mean baseline Mean after one month ICC
PACADI score 2.64 (2.25) 2.94 (1.70) 0.84* 2.42 (2.24) 2.78 (1.88) 0.74**
EQ-5D index 0.69 (0.32) 0.65 (0.28) 0.88* 0.75 (0.26) 0.67 (0.27) 0.83**
ESAS Pain at rest 0.85 (2.23) 1.85 (2.70) 0.74* 1.03 (2.10) 1.78 (2.47) 0.79**
ESAS Pain at movement 1.08 (2.29) 1.54 (2.26) 0.87* 1.22 (2.23) 1.59 (2.30) 0.67*
ESAS Fatigue 2.92 (2.93) 3.54 (3.23) 0.82* 2.61 (2.96) 2.65 (2.70) 0.63*
ESAS Nausea 1.00 (2.24) 0.15 (1.68) 0.19 1.16 (2.49) 1.25 (1.88) 0.02
ESAS Dyspnea 0.62 (2.22) 1.46 (1.90) 0.16 1.16 (2.46) 1.44 (1.87) 0.67*
ESAS Dry mouth 1.85 (2.44) 3.38 (2.93) 0.85* 2.00 (2.61) 2.55 (2.73) 0.71*
ESAS Loss of appetite 3.00 (3.49) 3.08 (3.69) 0.90** 2.03 (3.02) 2.75 (3.36) 0.81**
ESAS Anxiety 2.92 (3.59) 2.38 (2.57) 0.81* 2.59 (2.89) 1.97 (2.29) 0.71**
ESAS Depression 2.00 (2.97) 1.46 (1.94) 0.67* 1.34 (2.48) 1.31 (2.04) 0.64*
ESAS Sense of well-being 2.54 (3.02) 2.62 (2.60) 0.85* 2.28 (2.64) 2.44 (2.38) 0.72**
*p < 0.05.
**p < 0.001.
T. Heiberg et al. / Pancreatology 19 (2019) 971e978 975and that the sum score will be more relevant for research.5.1. Patients
The sample size target of 200 was based on the recommenda-
tion from the Women's Cancer Program at the Mayo Clinic,
Rochester, USA [20], indicating that sample sizes for testing should
include at least 200 cases and results should be replicated in at least
one additional sample. We have received a request from Sweden to
include the PACADI score into the Swedish National Pancreas
Registry which may provide an opportunity for the suggested
replication of our findings.
None of the patients or investigators knew the exact diagnoses
at baseline. Patients were all referred because of suspicion of PC. It
was only, mainly after histology (Table 2), that the exact diagnoses
were known. The awareness of a possible malignant disease could
have influenced the level of anxiety at baseline. A significant
reduction in anxiety was seen in the longitudinal data when the
patients eventually knew more about the exact diagnoses and the
disease impact (Table 6). Itchiness was another dimension that
changed significantly after baseline, which probably was caused bysurgery or stenting, to remove the blockage of lesions in the biliary
duct, and not by awareness of the diagnoses.5.2. Discrimination
Discriminant validity between disease groups as shown in this
study is another indicator of a strong disease specific feature of
PACADI. Significant differences between groups were also found in
“Fatigue” and “Bowel and/or digestive problems” as well as “loss of
appetite”. These dimensions showed the highest discriminant
property, which supports that they are highly relevant disease
specific measures.
The within group analyses revealed that the discriminant
property was only between PC and OML, i.e. between malignant
diseases. One explanation why the PACADI score was significantly
different between patients with PC and OML but was not significant
between patients with PC and NML, may be because many of the
patients with NMLs had pancreatitis which initially has a clinical
picture similar to PC [27], and tissue examination and/or imaging is
needed to confirm the correct diagnoses.
Table 6
Longitudinal data of PACADI score, EQ-5D index and ESAS over 12 months (baseline, after 1, 2, 3, 6, 9 and 12 months) in patients with pancreatic cancer (n's are based on
complete PACADI score at each measurement).
Baseline n¼ 199 1 month n¼ 94 2 months n¼ 81 3 months n¼ 85 6 months n¼ 76 9 months n¼ 61 12 months n¼ 51
PACADI score 3.38 (2.22) 3.41 (1.70) 3.06 (1.87) 2.72 (1.90)* 2.43 (1.66)** 2.24 (1.72)** 2.13 (1.75)*
PACADI dimensions
Pain/discomfort 2.89 (2.74) 3.70 (2.32)* 3.13 (2.29) 3.05 (2.49) 2.90 (2.36) 2.43 (2.60) 2.36 (2.10)
Anxiety 4.31 (3.23) 3.42 (2.50)** 3.14 (2.74)** 2.73 (2.62)** 2.57 (2.56)** 2.48 (2.67)** 2.30 (2.55)**
Loss of appetite 3.54 (3.50) 4.12 (2.99) 3.32 (2.95) 2.63 (2.86)* 2.00 (2.50)** 2.07 (2.59)* 1.78 (2.67)*
Itchiness 2.58 (3.77) 0.80 (1.91)** 1.10 (2.16)** 1.12 (2.20)** 0.88 (1.92)** 1.12 (2.04)** 1.00 (1.92)**
Fatigue 4.21 (2.94) 4.47 (2.81) 3.56 (2.77) 3.66 (2.79) 3.19 (2.55)* 2.78 (2.35)** 2.89 (2.44)*
Nausea 2.22 (2.84) 1.98 (2.37) 1.95 (2.42) 2.05 (2.44) 1.25 (2.01) 1.27 (2.09) 1.23 (1.82)
Dry mouth 3.04 (2.90) 3.24 (2.85)* 2.34 (2.54)* 2.34 (2.45)** 2.08 (2.38)** 2.19 (2.66) 1.70 (2.30)**
Bowel and/or digestive problems 3.27 (3.14) 3.52 (2.75) 3.35 (2.61) 3.49 (2.60) 3.06 (2.76) 3.17 (2.74) 2.57 (2.39)
EQ-5D index 0.62 (0.28) 0.57 (0.29) 0.64 (0.24) 0.64 (0.29) 0.73 (0.22) 0.73 (0.27) 0.75 (0.20)
ESAS dimensions
Pain at rest 1.82 (1.40) 1.89 (2.14) 1.80 (2.10) 1.72 (2.10) 1.74 (2.03) 1.30 (2.12) 1.30 (1.96)
Pain at movement 1.93 (2.48) 2.40 (2.30) 2.34 (2.24) 2.11 (2.45) 1.82 (2.09) 1.56 (2.28) 1.72 (2.26)
Fatigue 3.97 (3.14) 4.02 (2.83) 3.72 (2.55) 3.43 (2.63) 2.95 (2.28) 2.62 (2.55) 2.62 (2.31)*
Nausea 1.66 (2.66) 1.72 (2.36) 1.70 (2.44) 1.48 (2.14) 1.10 (1.96) 1.08 (1.93) 0.86 (1.68)
Dyspnea 1.26 (2.20) 1.48 (2.01) 1.82 (2.30)* 1.70 (2.32)* 1.14 (1.78) 1.46 (2.21) 0.92 (1.37)
Dry mouth 2.67 (2.98) 2.54 (2.72) 2.56 (2.76) 2.18 (2.57)* 1.92 (2.30) 1.97 (2.68) 1.50 (2.28)
Loss of appetite 3.66 (3.48) 3.33 (2.85) 3.87 (2.87) 2.69 (2.93) 2.13 (2.68)* 2.77 (2.56)* 1.29 (2.03)**
Anxiety 3.57 (3.20) 2.57 (2.47)** 2.67 (2.72)* 2.42 (2.58)* 2.27 (2.36)* 2.08 (2.49)* 1.79 (2.24)
Depression 2.71 (3.01) 2.31 (2.48) 2.24 (2.56) 2.33 (2.51) 1.90 (2.42) 2.03 (2.63) 1.51 (2.12)





Predictive validity of PACADI score, EQ-5D index and ESAS “sense of well-being” for
mortality within the first year after baseline in the three diagnostic groups (pre-
dictive validity).
PC n¼ 210 OML n¼ 109 NML n¼ 41
HRa p-value HRa p-value HRa p-value
PACADI score 1.09 0.02 1.05 0.47 1.20 0.18
EQ-5D index 0.68 0.17 0.42 0.10 0.29 0.18
ESAS sense of well-being 1.01 0.78 1.01 0.73 0.99 0.79
a Hazard Ratio from separate cox regression analyses adjusted for age and gender.
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The PACADI score correlated more strongly to EQ-5D index and
ESAS ”sense of well-being” than to the different components of
ESAS, which also supports that the PACADI score performs as a
global measure in patients with PC (Table 4).The ICC values for the
PACADI score were similar to EQ-5D index and ESAS ”sense of well-
being”. The higher ICC in patients with PC versus all patients
without PC further supports that the PACADI score performswell as
a disease specific measure for PC. One can question whether n¼ 14
is sufficient for a calculation of ICC. However, the minimum sample
size required to estimate the magnitude of the agreement between
observations is dependent on the actual value of ICC and the
number of observations of each subject. This means that for all of
our three global measures with two measurements, the n of 14 is
well beyond the minimum sample size required to calculate ICC
[28]. The number of patients reporting stable condition during the
first 3 months was low, explained by the high frequency of
comprehensive surgical procedures shortly after baseline, with an
expected initial decline in the proportion of patients with stable
condition [12].
The internal reliability of the scale of EQ-5D index was moderate
to very strong across visits, but very strong at all time points for
PACADI, indicating that the PACADI score possess high internal
consistency reliability.5.4. Longitudinal changes and prediction of mortality
Multiple t-tests were used to assess the changes over time. We
acknowledge that an adjustment for multiple testing could meet
the challenge with false positive findings. However, the use of such
adjustments in observational studies, where the number of tests
both presented and not presented are considerable, is controversial
[29]. We have thus chosen to keep the multiple t-tests without
adjustments, keeping in mind that the interpretation of the p-
values is not confirmatory but indicative of change.
The difference that was found at baseline between those who
completed the study and those who did not, may, not surprisingly,
reflect a better general health at baseline in those who completed.
Survivors with improved health status during follow-up have also
been observed in other studies [30]. “Bowel and/or digestive
problems” that worsens over time for patients with PC can poten-
tially be explained by all the digestion regulating hormones that are
produced in the pancreas.
The PACADI score and five of the eight dimensions improved
significantly in the longitudinal examinations. With an inflicting
disease like PC, an improvement over time may appear surprising.
The main explanation may be that curative and palliative in-
terventions impact PROMs positively [4]. An additional explanation
may be that those whowould report worsening PROMweremostly
deceased, supported by the decline in respondents from baseline
(n¼ 199) to 12months (n¼ 51). The improvement appearedmostly
at the 3-month visit at which time patients are expected to have
recovered after surgery [31].
The subsample at 12 months (n¼ 51) may seem small, however
it is 25.6% of the patients with PC who participated at baseline
(n¼ 199). Still this is a limitation. However, other longitudinal
studies of patients with PC have observed similar or lower retention
rates, influenced by the high mortality in these patients [12,26].
The significant high baseline levels and longitudinal improve-
ment in “Anxiety” and “Itchiness” in the PACADI score indicate that
these two dimensions play a clinically relevant role at an early stage
of the disease.
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EQ-5D index and ESAS “sense of well-being” supporting that the
PACADI score could be a valuable instrument in future intervention
trials in patients with PC.
Further, the PACADI score significantly predicted mortality un-
like EQ-5D index and ESAS “sense of well-being” (Table 7). Thus, the
PACADI score may be useful to identify patients who may benefit
from early and progressive intervention.
5.5. PACADI and ESAS
The two questionnaires PACADI score and ESAS have similar
features, sharing 6 dimensions which, not surprisingly, correlated
strongly with each other: “pain”, “anxiety”, “fatigue”, “nausea”,
“dry mouth”, “loss of appetite”. “Dyspnea” in ESAS is a compli-
mentary dimension to the PACADI score dimensions, with signifi-
cant discriminatory property between the groups. However,
contrary to the other measures, the mean value was significantly
higher with non-malignant diseases than the two other groups.
ESAS “dyspnea” and “depression” were not included dimensions in
the PACADI score, since they were not given sufficient priority by
the patients.
The two PACADI dimensions that were complementary to ESAS
dimensions were “Bowel and/or digestive problems” as well as
“itching”. Not all patients are affected by itching, but those who are,
reported that it should have high priority for improvement [14].
One other difference between the two instruments is the time
frame. ESAS focuses on “today”, whereas PACADI asks for the
perception during the last week. Symptoms may vary from one day
to the next. We used last week as time frame for PACADI to obtain a
report over more time than a single day, but recall bias may be an
issue. However, data from other studies have shown that daily and
7-day time frame scores correlate strongly, even though somewhat
influenced by the day of recording [32]. Thus, past week time frame
may contribute to highlight a more general disease experience.
5.6. Other PROM
Another disease specific PROM for PC has been developed by the
European Organization for Research and Treatment of Cancer
(EORTC) and contains 26 questions (QLQ-PAN26) divided into 17
scales, in addition to the basic cancer module with 30 questions,
divided into 15 scales. The extensive number of questions has
caused return rates too low to be included in analyses at follow-up
after one year [8]. Questions of sexuality in QLQ-PAN26 are less
frequently completed [8]. In the PACADI score, dimensions of
highest priority to patients were included, and sexuality was never
mentioned by the patients, potentially caused by lower relevance
[8,14].
Psychometric properties for QLQ-PAN26 (23 scales out of 26
questions) showed some variation in internal consistency
measured with Cronbach's alpha, which may indicate that some of
the questions were not conceptually consistent [33]. The PACADI
score had consistently very strong internal consistency reliability
(>0.8) across all visits. Convergent validity between QLQ PAN26 and
QLQ-C30 also showed variable values, but were generally strong
(r> 0.6).
Patient-Reported Outcomes Measurement Information System
(PROMIS) has now been developed for several cancer diagnoses,
but up to now, PC is not one of them [34]. Several advantages are
linked to PROMIS, like electronic versions and computer adaptive
testing (CAT) [34].
Clinical Benefit Response (CBR) is a measure that has frequently
been used in trials [11]. It has an algorithm that includes pain in-
tensity, analgesic consumption, residual pain, KarnofskyPerformance to measure physical function and weight loss over at
least 4 consecutive weeks [35]. CBR responders and non-
responders to treatment are calculated. CBR has recently been
suggested to be replaced by PROM [11] in evaluations, since PROM
has been shown to gain complementary information and a higher
response rate without losing substantial information. CBR requires
several time consuming measurements, whereas PROM question-
naires is completed by the patients and represent dimensions with
relevance and meaning based on the importance to the patients
[11].
5.7. The patient perspective
Some questionnaires include questions about health care per-
formance [36]. One issue may be whether such questions are sen-
sitive to the effect of new therapeutic agents. Development of
PROM usually has input from high impact professionals alongside
patients [8,37,38], providing a mixed message from different per-
spectives in one PROM. However, multiple studies have shown
discrepancies between opinions and responses between clinicians
and patients [13]. Thus, the validity of PROM from a patient
perspective would potentially increase by using patients rather
than health professionals as the main source for identification of
items to be included in the PROM.
Advantageous feasibility features of PROM include brevity and
relevance, which may influence the amount of missing data and
respondent rates [8]. Relevance to the target population (content
validity) is inherent when patients are the only source for selecting
dimensions of PROM and howmany questions to ask. For scientific
comparisons on a group level a weighted score reflecting the
relative importance of different dimensions to patients to express a
composite measure is informative and easy to communicate.
5.8. Weaknesses and strengths
One potential weakness in this study is the single-center design,
which means that the findings need to be validated in other cen-
ters, preferably in other countries. One benefit with a single center
versus multicenter approach can be reduced variability in trial
conduct and data collection by a consistent team and environment
[39]. A PACADI web site was established in 2013 [40] with an
increasing number of international visitors. Using Google analytics
at this web site since October 2017, we found that main stake-
holders abroad representing USA, China, Canada and Sweden have
expressed an interest in using PACADI for scientific purposes.
Importantly, some tools require a payment when used, which may
be a challenge for less affluent research groups and for use in daily
clinical practice. PACADI is freely available for academic purposes,
similar to the RAID and PsAID questionnaires [17e19].
One major strength in this psychometric study is the full range
of analyses that we were able to apply in this longitudinal obser-
vational study, with coherently supporting findings across
methods, eventually ending up with a feasible, valid, brief, patient
derived and disease specific measure for PC.
6. Conclusion
The current study examines both cross-sectional and longitu-
dinal psychometric properties across an extensive variety of ana-
lyses and demonstrates that the PACADI score keeps satisfactory
psychometric performance, also in comparison with the generic
EQ-5D index as well as the disease-specific ESAS “sense of well-
being”. We suggest that PACADI is eligible for use in clinical practice
as well as in scientific studies in the international community car-
ing about patients with PC.
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